Targeting the VEGF/vascular endothelial growth factor receptor (VEGFR) axis in tumours overexpressing VEGF was able to reverse the upregulation of checkpoint proteins on T cells [76], providing evidence that anti-angiogenic tyrosine kinase inhibitors (TKIs) may represent attractive targets for STS therapy when used in combination with immune checkpoint blockade. The gene discussed is VEGFA; the disease is neoplasm.